Capricor Therapeutics’ (CAPR) “Buy” Rating Reiterated at HC Wainwright

Capricor Therapeutics (NASDAQ:CAPRGet Free Report)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a report released on Tuesday, Benzinga reports. They currently have a $40.00 price target on the biotechnology company’s stock.

Separately, upgraded Capricor Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, January 24th.

Check Out Our Latest Stock Report on Capricor Therapeutics

Capricor Therapeutics Stock Performance

Shares of NASDAQ:CAPR opened at $5.44 on Tuesday. The firm’s 50 day simple moving average is $5.93 and its 200-day simple moving average is $4.59. Capricor Therapeutics has a one year low of $2.68 and a one year high of $8.22. The firm has a market cap of $171.36 million, a PE ratio of -6.25 and a beta of 4.06.

Capricor Therapeutics (NASDAQ:CAPRGet Free Report) last announced its quarterly earnings data on Thursday, February 29th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.21. The company had revenue of $12.09 million for the quarter, compared to analysts’ expectations of $5.80 million. Capricor Therapeutics had a negative return on equity of 299.67% and a negative net margin of 88.52%. Equities research analysts predict that Capricor Therapeutics will post -0.83 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Citigroup Inc. bought a new stake in Capricor Therapeutics during the third quarter valued at about $211,000. Vanguard Group Inc. boosted its holdings in shares of Capricor Therapeutics by 17.2% in the 1st quarter. Vanguard Group Inc. now owns 1,365,903 shares of the biotechnology company’s stock valued at $9,274,000 after buying an additional 200,499 shares in the last quarter. BNP Paribas Financial Markets purchased a new stake in Capricor Therapeutics during the first quarter valued at approximately $40,000. Finally, Jump Financial LLC acquired a new stake in Capricor Therapeutics in the fourth quarter valued at approximately $258,000. 21.68% of the stock is currently owned by hedge funds and other institutional investors.

About Capricor Therapeutics

(Get Free Report)

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.

Featured Stories

Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with's FREE daily email newsletter.